血液系统恶性肿瘤患者CAR-T治疗后严重细胞因子释放综合征早期预测新评分的推导与验证:一项多中心研究
在中国6家医院开展的多中心研究,训练队列87例多发性骨髓瘤患者,外部验证队列59例多发性骨髓瘤患者及68例急性淋巴细胞白血病或非霍奇金淋巴瘤患者,基于CAR-T输注后第1-2天45种细胞因子水平及临床特征构建包含CX3CL1、GZMB、IL4、IL6和PDGFAA的列线图,预测严重细胞因子释放综合征的偏倚校正AUC在训练队列为0.876(95%CI=0.871-0.882),两个外部验证队列分别为0.907(95%CI=0.899-0.916)和0.908(95%CI=0.903-0.913),校准图在所有队列中与理想线重叠。
要点
- 基于CAR-T输注后第1-2天45种细胞因子及临床特征构建含CX3CL1、GZMB、IL4、IL6和PDGFAA的列线图。
- 训练队列预测严重CRS的偏倚校正AUC为0.876(95%CI=0.871-0.882)。
- 外部验证队列MM的AUC为0.907(95%CI=0.899-0.916),ALL/NHL的AUC为0.908(95%CI=0.903-0.913)。
核心结论
- 开发了可在患者病情危重前预测其可能发生严重CRS的列线图,增进了对CRS生物学的理解,并可能指导未来的细胞因子导向治疗。
研究设计与样本
- 多中心研究,在中国6家医院开展。
- 训练队列纳入87例多发性骨髓瘤患者,外部验证队列纳入59例多发性骨髓瘤患者,另一外部验证队列纳入68例急性淋巴细胞白血病或非霍奇金淋巴瘤患者。
- 使用CAR-T细胞输注后第1-2天45种细胞因子水平及患者临床特征构建列线图。
主要发现
- 构建的列线图包含CX3CL1、GZMB、IL4、IL6和PDGFAA。
- 基于训练队列,列线图预测严重CRS的偏倚校正AUC为0.876(95%CI=0.871-0.882)。
- 外部验证队列MM的AUC为0.907(95%CI=0.899-0.916),外部验证队列ALL/NHL的AUC为0.908(95%CI=0.903-0.913)。
- 校准图(表观及偏倚校正)在所有队列中与理想线重叠。
关键数值与推荐
- 列线图纳入的指标为CX3CL1、GZMB、IL4、IL6和PDGFAA。
- 训练队列预测严重CRS的偏倚校正AUC为0.876(95%CI=0.871-0.882)。
- 外部验证队列MM的AUC为0.907(95%CI=0.899-0.916),ALL/NHL的AUC为0.908(95%CI=0.903-0.913)。
临床怎么用
- 作者认为该列线图可在患者病情危重前预测其可能发生严重CRS,增进了对CRS生物学的理解,并可能指导未来的细胞因子导向治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T (CAR-T) cell therapy is highly effective in inducing complete remission in haematological malignancies. Severe cytokine release syndrome (CRS) is the most significant and life-threatening adverse effect of this therapy. This multi-centre study was conducted at six hospitals in China. The training cohort included 87 patients with multiple myeloma (MM), an external validation cohort of 59 patients with MM and another external validation cohort of 68 patients with acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). The levels of 45 cytokines on days 1-2 after CAR-T cell infusion and clinical characteristics of patients were used to develop the nomogram. A nomogram was developed, including CX3CL1, GZMB, IL4, IL6 and PDGFAA. Based on the training cohort, the nomogram had a bias-corrected AUC of 0.876 (95% CI = 0.871-0.882) for predicting severe CRS. The AUC was stable in both external validation cohorts (MM, AUC = 0.907, 95% CI = 0.899-0.916; ALL/NHL, AUC = 0.908, 95% CI = 0.903-0.913). The calibration plots (apparent and bias-corrected) overlapped with the ideal line in all cohorts. We developed a nomogram that can predict which patients are likely to develop severe CRS before they become critically ill, improving our understanding of CRS biology, and may guide future cytokine-directed therapies.
引用
- Zhou L, Fu W, Wu S, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023. PMID: 37192741. doi:10.1111/bjh.18873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。